Sinopia Secures Phase II SBIR Grant from the National Institute of Dental and Craniofacial ...
Sinopia Biosciences awarded $2.2M Phase II SBIR grant from NIDCR to advance oral mucositis program using LEADS® platform, combining AI/ML and high-throughput screening for therapeutic target identification.
Highlighted Terms
Related News
Sinopia Biosciences, a San Diego-based biotech company, received a $2.2M Phase II SBIR grant from the National Institute of Dental and Craniofacial Research to advance its oral mucositis program using its LEADS® computational drug discovery platform.
Sinopia Biosciences awarded $2.2M Phase II SBIR grant from NIDCR to advance oral mucositis program using LEADS® platform, combining AI/ML and high-throughput screening.
Sinopia Biosciences awarded $2.2M Phase II SBIR grant from NIDCR to advance oral mucositis program using LEADS® platform, combining AI/ML and high-throughput screening for therapeutic target identification.